EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSTTRG00000006781
Gene Symbol: MAP2K2
1 Cross references
261 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSTTRG00000011220
Gene Symbol: MAP3K1
1 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSTTRG00000000772
Gene Symbol: MAP3K10
1 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSTTRG00000002286
Gene Symbol: MAP3K11
1 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSTTRG00000017175
Gene Symbol: MAP3K12
1 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSTTRG00000002272
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSTTRG00000002547
Gene Symbol: MAP3K5
1 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSTTRG00000011275
Gene Symbol: MAP3K9
1 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSTTRG00000009039
Gene Symbol: MAOA
1 Cross references
146 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSTTRG00000009085
Gene Symbol: MAOB
1 Cross references
330 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSTTRG00000017110
Gene Symbol: MGLL
1 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSTTRG00000004044
Gene Symbol: MLNR
1 Cross references
165 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).